Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
mTOR inhibitors
6 evidence topics · 9 sources
Everolimus for hypoglycemia refractory to somatostatin analogs in advanced insulinoma: ENETS 2023 guidance
Everolimus: approval status, hyperglycemic effect, and adverse effects in insulinoma
“The drug is currently approved for the treatment of adult patients with advanced, progressive, and both functioning and nonfunctioning well-differentiated panNET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The hyperglycemic effect of everolimus (and other mTOR inhibitors) is, therefore, a welcome side effect in the antiproliferative treatment of insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other major adverse effects of everolimus include skin rash, stomatitis, fatigue, gastrointestinal upset, pneumonitis, anemia, and opportunistic infections” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Everolimus in metastatic insulinoma with refractory hypoglycemia: French multicenter series
“Twelve patients with metastatic insulinoma and refractory hypoglycemia who were treated with everolimus between May 2007 and June 2011 were reviewed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After a median duration of 6.5 months (range 1-35+ months), median time to the first recurrence of symptomatic hypoglycemia was 6.5 months (range 0 to 35+ months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three patients discontinued everolimus because of cardiac and/or pulmonary adverse events at 1, 1.5, and 7 months after initiation, which led to two deaths.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Everolimus in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival (OS) was longest with SSA at 84.67 months, followed by CAPTEM at 81.67 months and everolimus at 74.07 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote